46 completed, 18 unknown, 13 recruiting, 8 terminated. 44 Phase 3, 26 Phase 2, 6 Not applicable, 6 Phase 4, 5 Phase 1.
Follow remdesivir: new trials by email Literature Review of remdesivir trials Research Report on remdesivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals Remdesivir, Survey Administration, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2025-12-23 | 2026-10-01 |
| Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients Remdesivir (RDV) - COVID - 19, Renal Transplant | Phase 2 | Recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 15 | 2025-09-01 | 2025-09-29 |
| Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV Remdesivir - Respiratory Syncytial Virus (RSV) | Phase 2 | Recruiting | PENTA Foundation | 120 | 2025-07-16 | 2025-07-23 |
| A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised ibuzatrelvir, remdesivir, placebo for ibuzatrelvir - COVID-19 Infection | Phase 3 | Recruiting | Pfizer | 300 | 2025-07-14 | 2026-10-14 |
| Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial Nirmatrelvir/ritonavir, Remdesivir - SARS CoV-2 Post-Acute Sequelae | Phase 4 | Recruiting | Mount Sinai Hospital, Canada | 118 | 2025-01-03 | 2025-01-24 |
| An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. Remdesivir - SARS-CoV-2 Infection, COVID-19 | Phase 4 | Completed | University of Derby | 73 | 2024-10-08 | 2026-02-20 |
| Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients combination therapy, SOC - COVID-19, SARS-CoV-2 | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2024-09-21 | 2024-09-25 |
| OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial Paxlovid 5 days, Paxlovid 10 days, Veklury - COVID-19, Immunodeficiency | Phase 2 | Recruiting | ANRS, Emerging Infectious Diseases | 256 | 2023-04-27 | 2026-10-19 |
| A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects Remdesivir, CX2101A, Placebo - COVID-19, Coronavirus Pneumonia | Phase 1 | Completed | Heronova Pharmaceuticals | 63 | 2022-12-26 | 2025-03-06 |
| Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir - COVID-19 | Phase 4 | Completed | Mansoura University Hospital | 265 | 2022-09-02 | 2023-07-25 |
| Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 Ivermectin - Covid19, COVID-19 Pneumonia | Unknown | Patrick Robinson | 1000 | 2022-05-01 | 2022-04-27 | |
| COVID-19 International Drug Pregnancy Registry Antiviral Agents, Monoclonal antibody - Covid19 | Recruiting | Pregistry | 2000 | 2021-12-01 | 2025-09-26 | |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) PF-07304814, Placebo, Remdesivir - COVID-19 | Phase 3 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 58 | 2021-09-15 | 2024-02-09 |
| Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19 Favipiravir, Remdesivir - COVID-19 | Phase 3 | Completed | Promomed, LLC | 217 | 2021-08-11 | 2022-01-11 |
| ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 Danicopan, Placebo, Remdesivir - COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 201 | 2021-08-03 | 2023-06-08 |
| OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA Remdesivir - Duration of Hospitalization, Clinical Manifestation of COVID-19 | Completed | Bernadette Dian Novita, MD.,PhD | 87 | 2021-08-01 | 2022-02-03 | |
| SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients) Remdesivir - Covid19 | Phase 4 | Unknown | Clinical Urology and Epidemiology Working Group | 202 | 2021-07-24 | 2022-07-15 |
| Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus Baricitinib, Dexamethasone, Remdesivir - COVID-19 Pneumonia | Phase 3 | Withdrawn | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 2021-07-10 | 2024-04-09 |
Showing 20 of 93. Sign in to see all of them.
COVID-19 (79) · Coronavirus Infections (17) · Severe Acute Respiratory Syndrome (14) · RNA Virus Infections (10) · Virus Diseases (10) · Coronaviridae Infections (9) · Nidovirales Infections (9) · Pneumonia (7) · Pneumonia, Viral (4) · Post-Acute COVID-19 Syndrome (3) · Hemorrhagic Fever, Ebola (2) · Lung Diseases (2) · Respiratory Syncytial Virus Infections (2) · Respiratory Tract Infections (2) · Acquired Immunodeficiency Syndrome (1)
National Institute of Allergy and Infectious Diseases (NIAID) (20) · Gilead Sciences (7) · Capital Medical University (2) · Duke University (2) · M Abdur Rahim Medical College and Hospital (2) · Nepal Health Research Council (2) · ANRS, Emerging Infectious Diseases (1) · ASST Fatebenefratelli Sacco (1) · Ahmed Essam (1) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Astana Medical University (1) · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (1) · Bernadette Dian Novita, MD.,PhD (1) · Biomed Industries, Inc. (1)
United States (42) · Spain (21) · United Kingdom (19) · Denmark (13) · Singapore (12) · France (10) · Japan (10) · Greece (9) · South Korea (9) · Switzerland (9) · Germany (8) · Italy (7) · Mexico (7) · Brazil (6) · Canada (6)
James Neaton, Prof. (6) · Jens Lundgren, Prof. (6) · Prof. James Neaton (3) · Akter Kamal, MD, PhD (2) · Samuel Brown, MD (2) · Andreas Barratt-Due, MD, PhD (1) · Andrew Badley, MD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Arif Malik, PhD (1) · Bernd Jilma, MD (1) · Bill Powderly, MD (1) · Brookie Best, PharmD, MAS (1) · Cheryl Renz, MD (1)
PMID 36695483, PMID 34473343, PMID 34350582, PMID 32445440, PMID 36442063, PMID 38618926, PMID 32423584, PMID 32821939, PMID 33148977, PMID 33264556, PMID 33306283, PMID 33356051, PMID 34928698, PMID 34953520, PMID 35817072, PMID 35939810, PMID 22263004, PMID 31774950, PMID 32267771, PMID 32304640, PMID 32401715, PMID 32448345, PMID 32615072, PMID 32647915, PMID 32678530, PMID 32706859, PMID 32800858, PMID 32876697, PMID 32969710, PMID 33129421, PMID 33217357, PMID 33227231, PMID 33234158, PMID 33240091, PMID 33268335, PMID 33278625, PMID 33293006, PMID 33389725, PMID 33394942, PMID 33509275, PMID 33624010, PMID 33631065, PMID 33709142, PMID 33715160, PMID 33760094, PMID 33969237, PMID 33990684, PMID 34048876, PMID 34133856, PMID 34192610
2015 (1), 2023 (1), UM1AI109565 (1)